|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
There have been numerous clinical trials of CDK4/6 inhibitors performed on various carcinomas including breast cancer.
|
29522364 |
2018 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Dysregulated activation of the CDK4/6 kinases is a hallmark of most mammary-derived carcinomas.
|
27748766 |
2017 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas.
|
27662657 |
2016 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Loss of p16/Rb protein (pRb) expression and overexpression of cyclin D1/CDK4 were observed in 49%/40% and 37%/37% of gastric carcinomas, respectively.
|
18484097 |
2008 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We analyzed CDK4 gene alterations and mRNA expression in a series of carcinomas of the larynx, and the results were compared to CCND1 expression and clinicopathological characteristics of the patients.
|
17139501 |
2007 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Most normal or non-neoplastic epithelia showed more p16 and CDK4 expression in the nucleus than their adjacent adenomas and carcinomas.
|
17072968 |
2006 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
Among carcinomas, Cdk4 and phospho-Rb levels were positively correlated with cell proliferation.
|
14522882 |
2003 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Of the analyzed proliferative factors PCNA, cyclin A, cyclin D, cdk2, cdk4 and cell cycle phases only cyclin D, cdk4 and the cell cycle phases were up-regulated in growing carcinomas.
|
11788907 |
2002 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Expression of the RB protein, allelic imbalance of the RB gene and amplification of the CDK4 gene in metaplasias, dysplasias and carcinomas in Barrett's oesophagus.
|
11299766 |
2001 |
|
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Fifty-three neuroendocrine lung tumors (24 carcinoids, one atypical carcinoid, five large-cell neuroendocrine carcinomas, and 23 small-cell lung carcinomas) were investigated for immunocytochemical expression of several gene products, i.e., p53, Rb, bcl-2, c-kit, mdm-2, cdk-4, p21 proteins, and proliferation index as assessed by MIB-1.
|
10937049 |
2000 |
|
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We examined the frequency of INK4a-ARF, p53, and CDK4 mutations in skin carcinomas from patients with xeroderma pigmentosum (XP), a rare autosomal disease that is associated with a defect in DNA repair and that predisposes patients to skin cancer.
|
11078762 |
2000 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Ectopic expression of cyclin D2 or amplification of CDK4 does not occur at a significant frequency in urothelial carcinomas.
|
9738978 |
1998 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
CDK4 gene amplification occurred in 9 of 81 glioblastomas (11%), but was rare in other neoplasms, including low-grade and anaplastic gliomas, meningiomas, medulloblastomas and metastatic carcinomas (only 6 of 274 cases).
|
8811128 |
1996 |
|
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
p16 (CDKN2/cyclin-dependent kinase-4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines.
|
8821952 |
1996 |